Genmab — Oktober 2022
-
God morgen.
-
Godmorgen.
-
bibob...Det er typisk for en periode med store fald i stort set alle aktier. Vi kan så glæde os over, at der er godt gang i debatsektionen. Der dobbelt så mange besøgende som læser med her sammenlignet med samme periode i de foregående år.
-
Zealand Pharma-chatten vågnede op fredag. Jeg tror der bliver travlt i den fremover. Vi er mange som har ventet på de gode data i indenfor korttarmsyndrom.
-
Godmorgen
-
Godmorgen.
-
Asien: Ferietyndt let faldende marked trods plusser i Tokyo https://www.proinvestor.com/investornyt/885602/asien-ferietyndt-let-faldende-marked-trods-plusser-i-tokyo
-
Mandagens danske avisuddrag med retssag, recession og brudte løfter https://www.proinvestor.com/investornyt/885605/mandagens-danske-avisuddrag-med-retssag-recession-og-brudte-lofter
-
Aktier/tendens: Vestas i fokus før ventet rød start på fjerde kvartal https://www.proinvestor.com/investornyt/885620/aktier-tendens-vestas-i-fokus-for-ventet-rod-start-pa-fjerde-kvartal
-
Congress | #SOHO22 Alex Herrera from
@cityofhope
presents updated results from a phase II study where camidanlumab tesirine demonstrated an ORR of 70.1%, median DOR of 13.7 months and median PFS of 9.1 months in patients with R/R CHL https://twitter.com/lymphomahub/status/1575986164598964224
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind